Your output reaches patients.
The first-in-human study reported 100% specificity for durable PFA lesion prediction at three-month follow-up, peer-reviewed in Europace, February 2025. What the team builds is what the electrophysiologist sees.
Cardiac ablation is still performed blind. A small team in Madrid is changing that, across optics, catheter hardware, and clinical AI. If you want your work inside a real procedure, this is the place to do it.
The device presented is under preclinical/clinical investigation. It is not FDA approved nor CE labelled.
AblaView is not a research project looking for an application. The system has been used in humans, the results are peer-reviewed, and the work now is turning that into a device that ships.
The first-in-human study reported 100% specificity for durable PFA lesion prediction at three-month follow-up, peer-reviewed in Europace, February 2025. What the team builds is what the electrophysiologist sees.
Optics, catheter hardware, production, and the Clinical AI Engine are each held by a few people. There is no layer between you and the decision.
Twelve years of catheter-focused R&D, a 25 TB PS-OCR dataset paired with histology, and 860+ preclinical ablations. You start from a working system, not a whiteboard.
Electronics and optics integration across the console and catheter platform.
Catheter production and quality control.
Engineering support for preclinical and clinical studies.
Send the form below, with your CV attached to the email it opens.
A conversation about your work and what the role actually involves.
A working session with the people you would sit beside. No trick questions.
An answer either way, with the reasoning. Candidates are not left waiting.
Do not see your role? Write to info@ablaview.com with what you do and why this problem interests you. Speculative applications from strong engineers are read.